BioTek’s Gen5 Software Offers CVB Relative Potency Solution

12 Aug 2014
Charlotte Moore
Administrator / Office Personnel

Industry news

BioTek has announced the availability of customizable pre-programmed protocols for Gen5™ Data Analysis Software designed to estimate Relative Potency according to the requirements of the USDA APHIS Center for Veterinary Biologics (CVB) guidelines published March 14, 2014.

The CVBSOP0101.01 establishes the criteria that veterinary vaccine producers must use to estimate the relative potency of their test serials prior to submission for licensing through the CVB. Several pre-programmed Gen5 protocols addressing both the full dose response and the linear methods for calculation are available for free download from BioTek’s website. BioTek’s Gen5 capability provides CVB compliant laboratories with a convenient option to meet the stringent requirements of this SOP.

BioTek will be hosting a webinar on September 25, 2014 where they will describe the use of Gen5 software to estimate relative potency values per the CVB requirements. Registration for the webinar can be accessed by clicking the company website link below.

Agilent BioTek Gen5 Software for Detection

Agilent Technologies

Agilent BioTek Gen5 software for Agilent BioTek multimode and single-mode microplate readers is an integrated tool for endpoint, kinetic, spectral scanning, and well area scanning. It controls all the functions of the plate reader and has powerful data analysis capabilities for a broad range of applications. Gen5 microplate reader software is also used to integrate BioTek plate readers to BioTek BioStack and other automated systems.

(83)

Links

Tags

Development SoftwareComputational techniques used in both the chemistry and biology aspects of drug development, for data acquisition, data analysis, processing and storage. Software is used for analysis of ADME results, toxicology, clinical trials and regulatory processes. Veterinary DrugsVaccine DevelopmentVaccine development focuses on creating immunizations to protect against infectious diseases. The process involves identifying antigens, developing and testing vaccine efficacy, and ensuring safety through preclinical testing and multiple clinical trial phases. Scientists use various approaches, including weakened or inactivated viruses, protein subunits, or mRNA. Advanced platforms and rapid diagnostic tools aid in vaccine research and testing. Explore vaccine development solutions in our peer-reviewed product directory; compare products, read reviews, and get pricing directly from manufacturers.
BioTek’s Gen5 Software Offers CVB Relative Potency Solution